Patient and Physician Preference for an Intracanalicular Dexamethasone Insert for Treating Inflammation and Pain Following Cataract Surgery | ASCRS
Patient and Physician Preference for an Intracanalicular Dexamethasone Insert for Treating Inflammation and Pain Following Cataract Surgery
May 2020
Meeting: 2020 Virtual Annual Meeting
Session: SPS-111 Cataract Surgery - Medications
Authors: Cathleen M. McCabe, MD, John Berdahl MD, Sydney Tyson MD, MPH, Inder Singh MD, Srilatha Vantipalli PhD, Jamie Lynne Metzinger MPH, MSc, Michael Goldstein MBA, MD
You do not have access to this library

This content is accessible only to 2020 ASCRS Virtual Annual Meeting attendees. If you attended the virtual meeting, please log in with the account associated with your virtual meeting registration.  To log in, click the teal "Login" button in the upper right-hand corner of this page.

Standard of care post-ocular surgery includes corticosteroid eyedrops, a burden for patients. DEXTENZA® (dexamethasone ophthalmic insert), a resorbable intracanalicular insert delivering a tapering dose over 30 days, is intended to eliminate this burden. Here we evaluate physician and patient reported outcomes regarding DEXTENZA insertion.

Three prospective, double-masked, parallel-arm, vehicle-controlled Phase 3 studies were conducted. Adult subjects (n=923; >18 years) who had undergone cataract surgery with intraocular implantation on Day 1 were randomized to receive either DEXTENZA (DEX; n=538) or Placebo (PV; n=385), immediately following surgery. Post-hoc pooled analyses of the three trials was conducted to capture the physician experience by evaluating ease of product use and ease of subsequent visualization in the clinical setting. Additionally, in one trial, patient experience with DEXTENZA was captured on a 5-point Likert scale (1=worst; 5=best) via written (N=216) or phone (N=25) end-of-study questionnaires.

Investigators rated the product as easy or moderately easy to insert in 97.7% of DEXTENZA eyes. DEXTENZA was visualized in 99.5% of subjects at Day 14; inserts were rated as easy or moderately easy to visualize in >95% of eyes. DEXTENZA subjects reported high scores (scores of 3 and above) with respect to relief of eye pain and discomfort, comfort (96%), convenience (97%) and overall satisfaction (93%) and was significantly better compared to placebo (p < 0.01). Subjects thought the insert helped compliance (93%), they would be likely to ask for the insert again (93%), and likely to recommend it to others (95%).

DEXTENZA was rated positively by physicians and patients. From the physician’s perspective, DEXTENZA was easy to insert and visualize throughout postop period. From the patient perspective, DEXTENZA helped with compliance and were likely to request again. Monitoring insert presence overtime ensures continuous drug delivery compared to via drops.
View More Presentations from this Session

This presentation is from the session "SPS-111 Cataract Surgery - Medications" from the 2020 ASCRS Virtual Annual Meeting held on May 16-17, 2020.

We use cookies to measure site performance and improve your experience. By continuing to use this site, you agree to our Privacy Policy and Legal Notice.